Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

High prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.

Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borras E, Hasanov M, Varadhachary GR, Maitra A, Katz MHG, Feng L, Futreal PA, Fogelman DR, Vilar E, McAllister F.

Cancer Prev Res (Phila). 2018 Oct 1. pii: canprevres.0014.2018. doi: 10.1158/1940-6207.CAPR-18-0014. [Epub ahead of print]

PMID:
30274973
2.

Coxiella and Bartonella spp. in bats (Chiroptera) captured in the Brazilian Atlantic Forest biome.

Ferreira MS, Guterres A, Rozental T, Novaes RLM, Vilar EM, Oliveira RC, Fernandes J, Forneas D, Junior AA, Brandão ML, Cordeiro JLP, Del Valle Alvarez MR, Althoff SL, Moratelli R, Cordeiro-Estrela P, Silva RCD, Lemos ERS.

BMC Vet Res. 2018 Sep 10;14(1):279. doi: 10.1186/s12917-018-1603-0.

3.

Indexing dialysis dose for gender, body size and physical activity: Impact on survival.

Sridharan S, Vilar E, Davenport A, Ashman N, Almond M, Banerjee A, Roberts J, Farrington K.

PLoS One. 2018 Sep 7;13(9):e0203075. doi: 10.1371/journal.pone.0203075. eCollection 2018.

4.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jul 3. doi: 10.1093/annonc/mdy221. [Epub ahead of print] No abstract available.

PMID:
29982323
5.

Body Composition, Dietary, and Gustatory Function Assessment in People With Alzheimer's Disease.

Martín ISM, Barato VP, Oliva SL, Rodríguez M, Yurrita LC, Cabañas MJC, Rojo SS, de la Calle L, Díaz EÁ, Santos YQ, Pascual PE, Nieto MV, Vilar EG.

Am J Alzheimers Dis Other Demen. 2018 Jan 1:1533317518782173. doi: 10.1177/1533317518782173. [Epub ahead of print]

PMID:
29916258
6.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

PMID:
29710228
7.

Corrigendum: Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing.

Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, Gordillo M, Xiang JZ, Maxfield FR, Lipkin S, Evans T, Chen S.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526a.

PMID:
29634683
8.

Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.

Zhang Y, Zoltan M, Riquelme E, Xu H, Sahin I, Castro-Pando S, Montiel MF, Chang K, Jiang Z, Ling J, Gupta S, Horne W, Pruski M, Wang H, Sun SC, Lozano G, Chiao P, Maitra A, Leach SD, Kolls JK, Vilar E, Wang TC, Bailey JM, McAllister F.

Gastroenterology. 2018 Jul;155(1):210-223.e3. doi: 10.1053/j.gastro.2018.03.041. Epub 2018 Mar 29.

PMID:
29604293
9.

Pharmacogenomics: time to rethink its role in precision medicine.

Willis JA, Vilar E.

Ann Oncol. 2018 Feb 1;29(2):293-295. doi: 10.1093/annonc/mdx780. No abstract available.

PMID:
29236957
10.

Nevus lipomatosus cutaneous superficialis.

Lima CDS, Issa MCA, Souza MB, Góes HFO, Santos TBPD, Vilar EAG.

An Bras Dermatol. 2017 Sep-Oct;92(5):711-713. doi: 10.1590/abd1806-4841.20175217.

11.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688.

PMID:
29069279
12.

Targeted Therapy for Cancer-Associated Fibroblasts: Are We There Yet?

Barnett RM, Vilar E.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx131. No abstract available.

PMID:
28922783
13.

Clinical utility of circulating cell-free DNA in advanced colorectal cancer.

Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V.

PLoS One. 2017 Aug 29;12(8):e0183949. doi: 10.1371/journal.pone.0183949. eCollection 2017.

14.

In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation.

Borras E, Chang K, Pande M, Cuddy A, Bosch JL, Bannon SA, Mork ME, Rodriguez-Bigas MA, Taggart MW, Lynch PM, You YN, Vilar E.

Cancer Prev Res (Phila). 2017 Oct;10(10):580-587. doi: 10.1158/1940-6207.CAPR-17-0058. Epub 2017 Aug 1.

15.

Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention.

Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S.

Cancer Metastasis Rev. 2017 Jun;36(2):289-303. doi: 10.1007/s10555-017-9675-z. Review.

16.

Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis.

Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, Lopez-Doriga A, San Lucas FA, Sanjuan X, Paules MJ, Taggart MW, Davies GE, Ehli EA, Fowler J, Moreno V, Pineda M, You YN, Lynch PM, Lazaro C, Navin NE, Scheet PA, Hawk ET, Capella G, Vilar E.

Clin Cancer Res. 2017 Oct 1;23(19):5936-5947. doi: 10.1158/1078-0432.CCR-17-0821. Epub 2017 Jun 23.

17.

Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing.

Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, Gordillo M, Xiang JZ, Maxfield FR, Lipkin S, Evans T, Chen S.

Nat Med. 2017 Jul;23(7):878-884. doi: 10.1038/nm.4355. Epub 2017 Jun 19. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

18.

Refining prognosis in early-stage colorectal cancer: one or multiple genes at a time?

Willis JA, Vilar E.

Ann Oncol. 2017 Aug 1;28(8):1686-1688. doi: 10.1093/annonc/mdx272. No abstract available.

PMID:
28549076
19.

Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer.

Leung ML, Davis A, Gao R, Casasent A, Wang Y, Sei E, Vilar E, Maru D, Kopetz S, Navin NE.

Genome Res. 2017 Aug;27(8):1287-1299. doi: 10.1101/gr.209973.116. Epub 2017 May 25.

20.

Sweet's syndrome associated with Crohn's disease.

Lima CDS, Pinto RDB, Góes HFO, Salles SAN, Vilar EAG, Lima CDS.

An Bras Dermatol. 2017 Mar-Apr;92(2):263-265. doi: 10.1590/abd1806-4841.20175298.

21.

Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?

Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart MW, Wu J, Scheet P, Kopetz S, You YN, Vilar E.

Clin Cancer Res. 2017 Sep 1;23(17):5246-5254. doi: 10.1158/1078-0432.CCR-16-2994. Epub 2017 May 18.

22.

SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin.

Lo YH, Noah TK, Chen MS, Zou W, Borras E, Vilar E, Shroyer NF.

Gastroenterology. 2017 Jul;153(1):205-218.e8. doi: 10.1053/j.gastro.2017.03.048. Epub 2017 Apr 5.

PMID:
28390865
23.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

24.

Pruritic folliculitis of pregnancy.

Delorenze LM, Branco LG, Cerqueira LF, Vasques WB, Salles SA, Vilar EG.

An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):66-68. doi: 10.1590/abd1806-4841.20164735.

25.

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.

Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA.

Genes Dev. 2017 Feb 15;31(4):370-382. doi: 10.1101/gad.293449.116. Epub 2017 Mar 13.

26.

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S.

PLoS One. 2017 Mar 7;12(3):e0173345. doi: 10.1371/journal.pone.0173345. eCollection 2017. Erratum in: PLoS One. 2017 May 17;12 (5):e0178275.

27.

The Effect of Intra-Dialytic Exercise on Inflammation and Blood Endotoxin Levels.

Wong J, Davis P, Patidar A, Zhang Y, Vilar E, Finkelman M, Farrington K.

Blood Purif. 2017;44(1):51-59. doi: 10.1159/000455059. Epub 2017 Feb 28.

PMID:
28241125
28.

Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.

Maletzki C, Huehns M, Bauer I, Ripperger T, Mork MM, Vilar E, Klöcking S, Zettl H, Prall F, Linnebacher M.

Mol Carcinog. 2017 Jul;56(7):1753-1764. doi: 10.1002/mc.22632. Epub 2017 Mar 30.

PMID:
28218421
29.

Identification of MSH2 inversion of exons 1-7 in clinical evaluation of families with suspected Lynch syndrome.

Mork ME, Rodriguez A, Taggart MW, Rodriguez-Bigas MA, Lynch PM, Bannon SA, You YN, Vilar E.

Fam Cancer. 2017 Jul;16(3):357-361. doi: 10.1007/s10689-016-9960-y.

30.

Universal Genetic Testing for Younger Patients With Colorectal Cancer.

Vilar E, Stoffel EM.

JAMA Oncol. 2017 Apr 1;3(4):448-449. doi: 10.1001/jamaoncol.2016.5193. No abstract available.

PMID:
27978567
31.

Is Endotoxemia in Stable Hemodialysis Patients an Artefact? Limitations of the Limulus Amebocyte Lysate Assay and Role of (1→3)-β-D Glucan.

Wong J, Zhang Y, Patidar A, Vilar E, Finkelman M, Farrington K.

PLoS One. 2016 Oct 20;11(10):e0164978. doi: 10.1371/journal.pone.0164978. eCollection 2016.

32.

Measuring Residual Renal Function in Hemodialysis Patients without Urine Collection.

Wong J, Kaja Kamal RM, Vilar E, Farrington K.

Semin Dial. 2017 Jan;30(1):39-49. doi: 10.1111/sdi.12557. Epub 2016 Oct 18. Review.

PMID:
27757995
33.

Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam.

Ertem FU, Zhang W, Chang K, Mohaiza Dashwood W, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH.

Int J Cancer. 2017 Jan 15;140(2):460-468. doi: 10.1002/ijc.30458. Epub 2016 Oct 18.

34.

Attitudes in Patients with Autosomal Dominant Polycystic Kidney Disease Toward Prenatal Diagnosis and Preimplantation Genetic Diagnosis.

Swift O, Vilar E, Rahman B, Side L, Gale DP.

Genet Test Mol Biomarkers. 2016 Dec;20(12):741-746. doi: 10.1089/gtmb.2016.0050. Epub 2016 Sep 30.

PMID:
27689416
35.

Scaling Hemodialysis Target Dose to Reflect Body Surface Area, Metabolic Activity, and Protein Catabolic Rate: A Prospective, Cross-sectional Study.

Sridharan S, Vilar E, Davenport A, Ashman N, Almond M, Banerjee A, Roberts J, Farrington K.

Am J Kidney Dis. 2017 Mar;69(3):358-366. doi: 10.1053/j.ajkd.2016.07.025. Epub 2016 Sep 20.

PMID:
27663037
36.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

37.

A comparative study of blood endotoxin detection in haemodialysis patients.

Wong J, Davies N, Jeraj H, Vilar E, Viljoen A, Farrington K.

J Inflamm (Lond). 2016 Jul 30;13:24. doi: 10.1186/s12950-016-0132-5. eCollection 2016.

38.

DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.

de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S, Bednarski B, Messick CA, Skibber JM, Feig BW, Lynch PM, Vilar E, You YN.

J Clin Oncol. 2016 Sep 1;34(25):3039-46. doi: 10.1200/JCO.2016.66.6826. Epub 2016 Jul 18.

39.

Scleredema of Buschke associated with difficult-to-control type 2 diabetes mellitus.

Lemes LR, Vilela GM, Durães SM, Vilar EA.

Rev Assoc Med Bras (1992). 2016 May-Jun;62(3):199-201. doi: 10.1590/1806-9282.62.03.199.

40.

Rapid and powerful detection of subtle allelic imbalance from exome sequencing data with hapLOHseq.

San Lucas FA, Sivakumar S, Vattathil S, Fowler J, Vilar E, Scheet P.

Bioinformatics. 2016 Oct 1;32(19):3015-7. doi: 10.1093/bioinformatics/btw340. Epub 2016 Jun 10.

41.

Genomic Landscape of Colorectal Mucosa and Adenomas.

Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E.

Cancer Prev Res (Phila). 2016 Jun;9(6):417-27. doi: 10.1158/1940-6207.CAPR-16-0081. Epub 2016 May 24.

42.

Eczema-Like Psoriasiform Skin Reaction due to Brazilian Keratin Treatment.

Gavazzoni-Dias MF, Rochael M, Vilar E, Tanus A, Tosti A.

Skin Appendage Disord. 2016 Feb;1(3):156-62. doi: 10.1159/000442529. Epub 2016 Jan 13.

43.

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S.

Ann Oncol. 2016 Jun;27(6):1068-74. doi: 10.1093/annonc/mdw073. Epub 2016 Feb 18.

PMID:
27045102
44.

Identification of a novel PMS2 alteration c.505C>G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency.

Mork ME, Borras E, Taggart MW, Cuddy A, Bannon SA, You YN, Lynch PM, Ramirez PT, Rodriguez-Bigas MA, Vilar E.

Fam Cancer. 2016 Oct;15(4):587-91. doi: 10.1007/s10689-016-9902-8.

45.

Aspirin for Cancer Prevention: One Step Closer.

Vilar E, Maresso KC, Hawk ET.

JAMA Oncol. 2016 Jun 1;2(6):770-1. doi: 10.1001/jamaoncol.2015.6395. No abstract available.

PMID:
26939883
46.

Reply to L.B. Saltz.

Mork ME, You YN, Vilar E.

J Clin Oncol. 2016 May 1;34(13):1560-1. doi: 10.1200/JCO.2015.66.2049. Epub 2016 Feb 29. No abstract available.

PMID:
26926688
47.

Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin.

Wong J, Sridharan S, Berdeprado J, Vilar E, Viljoen A, Wellsted D, Farrington K.

Kidney Int. 2016 May;89(5):1090-1098. doi: 10.1016/j.kint.2015.12.042. Epub 2016 Feb 26.

48.

PARACOCCIDIOIDOMYCOSIS IN A RENAL TRANSPLANT RECIPIENT.

Góes HF, Durães SM, Lima Cdos S, Souza MB, Vilar EA, Dalston MO.

Rev Inst Med Trop Sao Paulo. 2016;58:12. doi: 10.1590/S1678-9946201658012. Epub 2016 Feb 23.

49.

The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients.

Sivalingam M, Vilar E, Mathavakkannan S, Farrington K.

BMC Nephrol. 2015 Dec 29;16:218. doi: 10.1186/s12882-015-0212-4.

50.

Plasma Levels of Middle Molecules to Estimate Residual Kidney Function in Haemodialysis without Urine Collection.

Vilar E, Boltiador C, Wong J, Viljoen A, Machado A, Uthayakumar A, Farrington K.

PLoS One. 2015 Dec 2;10(12):e0143813. doi: 10.1371/journal.pone.0143813. eCollection 2015.

Supplemental Content

Support Center